Clinical Trials About "Boston Scientific acquires nVision Medical 275m deal" RSS

07:09 EST 21st November 2018 | BioPortfolio

We list hundreds of Clinical Trials about "Boston Scientific acquires nVision Medical 275m deal" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "Boston Scientific acquires nVision Medical 275m deal" on BioPortfolio

We have published hundreds of Boston Scientific acquires nVision Medical 275m deal news stories on BioPortfolio along with dozens of Boston Scientific acquires nVision Medical 275m deal Clinical Trials and PubMed Articles about Boston Scientific acquires nVision Medical 275m deal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Boston Scientific acquires nVision Medical 275m deal Companies in our database. You can also find out about relevant Boston Scientific acquires nVision Medical 275m deal Drugs and Medications on this site too.

Showing "Boston Scientific acquires nVision Medical 275m deal" Clinical Trials 1–25 of 8,300+

Extremely Relevant

The Boston Scientific ENOVUS Trial

A prospective, actively controlled, consecutively enrolling, non-randomized multi center clinical evaluation of the safety and efficacy of the Boston Scientific ENOVUS AAA Endograft when used in the treatment of patients with AAA (Treatment Group) as compared to patients treated with conventional open surgery (Control Group).

Boston Scientific COMET Wire Validation Study

Summary of Study Aims To assess, in a randomised fashion: 1. performance of Boston Scientific Pressure Wire versus St Jude Pressure Wire 2. performance of Boston Scientific Pressure Wire versus Boston Scientific Pressure Wire 3. performance of St Jude Pressure Wire versus St Jude Pressure Wire


Predict Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia

Researchers are trying to see if the Nvision® Imaging System (VLE) can accurately determine the risk of recurrent Barrett's esophagus in patients with Barrett's esophagus which have been clear of disease.

The Boston Scientific ACCESS Trial

The Boston Scientific ACCESS trial seeks to study the safety and to evaluate the success of the Fusion™ Vascular Access Graft for patients in need of early vascular access for hemodialysis.

Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project

To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal Artery (PPA) lesions.

The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study

This study is designed to evaluate the effect of pacing on post-MI patients.

Clinical Use of an Artificial Rectal Sphincter Device, Trade Name Fenix

This application is to obtain approval for clinical use of the Fenix, a Humanitarian Use Device. The Fenix device was just approved by the FDA as a Humanitarian Exempt Device for fecal incontinence. It has only been utilized in small numbers in Europe. There was a previous device produced by American Medical Systems, who sold their artificial bowel sphincter to Boston Scientific. Boston Scientific has elected to not continue the manufacturing of the artificial bowel sphincter. ...

Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation

To obtain data for the Rhythmia™ Mapping System in conjunction with Boston Scientific Open-Irrigated (OI) Catheters for ablation of Paroxysmal Atrial Fibrillation (PAF) according to current international and local guidelines. Primary objective: To assess acute and long-term outcomes for the Rhythmia Mapping System in conjunction with Boston Scientific Open-Irrigated Ablation Catheters to treat de novo Paroxysmal Atrial Fibrillation. De Novo PAF is defined as subjects undergo...

Combining Mechanisms for Better Outcomes (COMBO)

To evaluate the effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities as compared to conventional SCS in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System.

Study to Characterize the Effects of Programming Spinal Cord Stimulation (SCS) in Patients Undergoing a Boston Scientific (BSC) SCS Temporary Trial

This is a prospective, multi-center, non-randomized, exploratory, single-arm study characterize the effects of programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial

Study to Characterize Acute and Chronic Directional Aspects of Deep Brain Stimulation

The primary objective is to characterize the programming effects of Boston Scientific Vercise™ PC System using the DBS Directional Lead for bilateral STN DBS for the treatment of Parkinson's disease in acute and chronic settings.

NAVITAS: A Study to Characterize the Relationship Between Select Objective Metrics and Clinical Outcomes in Chronic Pain Patients Treated With Boston Scientific Neurostimulation Systems

The objective of the study is to characterize the relationship between select objective metrics and clinical outcomes in chronic pain patients treated with Boston Scientific commercially approved neurostimulation systems.

Clinical Study of the Boston Scientific Paclitaxel-Coated PTA(Percutaneous Transluminal Angioplasty) Balloon Catheter (Ranger™ and Ranger™ SL (OTW) DCB) in China

This clinical study is a prospective, non-randomized, multicenter study to demonstrate the acceptable safety and performance of angioplasty with the Ranger DCB in native femoropopliteal artery lesions. It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Ranger DCB catheter. Approximately 123 patients with femoropopliteal artery lesions will be enrolled. All lesions will be treated with the Ranger DCB. Up to 15 clinica...

Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions

The purpose of this study is to establish the safety and long-term effectiveness of coronary stenting with the ABT 578-eluting balloon expandable stent (Medtronic, Minneapolis, MN) vs. the sirolimus-eluting balloon expandable stent (Cordis Johnson & Johnson, Warren, New Jersey) and the paclitaxel-eluting stent (Taxus liberte, Boston Scientific) for the treatment of coronary stenosis in routine clinical practice.

Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

The trial has the following primary objective: To compare the safety and effectiveness of primary acute MI intervention with ABT 578-eluting balloon expandable stent (Medtronic, Minneapolis, MN) vs. sirolimus-eluting balloon expandable stent (Cordis Johnson & Johnson, Warren, New Jersey) vs. paclitaxel-eluting stent (Taxus Liberte, Boston Scientific).

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®). The XIENCE V® arm will be compared to an active control, represented by the FDA-approved TAXUS® EXPRESS2™ Paclitaxel-Eluting Coronary Stent System (TAXUS®), commercially available from Boston Scientific. TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is manufactured by Boston Scientific.

Optical Coherence Tomography for Drug Eluting Stent Safety

Increasing lesion complexity in percutaneous coronary interventions (PCI) has warranted the use of overlapping drug-eluting stents. Whether the substantial impairment of arterial healing observed at sites of overlap in preclinical pathologic studies persists in patients undergoing PCI is unknown. Consecutive patients with long lesions in native coronary vessels requiring stents in overlap are prospectively randomized to receive multiple sirolimus-,paclitaxel polymer-or zotarol...

Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication

Boston Medical Center provides care to cancer patients on oral cancer medications through the use of Boston Medical Center Specialty Pharmacy (BMC SP). The use of oral medications in cancer treatments is relatively new and unfortunately, very little is known about adherence in cancer patients. This study will evaluate the influence of a pharmacist-driven medication management program on adherence and persistence rates. Boston Medical Center's Specialty Pharmacy Adherence Progra...

Comparing the Franseen and Fork-top Needles for EUS-guided Fine-needle Biopsy of Solid Mass Lesions.

This will be a randomized controlled trial of all the patients referred to University of Arkansas Medical for Medical Sciences (UAMS) for endoscopic ultrasound (EUS) guided biopsy of solid mass lesions. EUS guided tissue acquisition will be performed in all these patients using both needle types (22-gauge Franseen Fine Needle Biopsy (FNB) (Acquire, Boston Scientific Corporation, Natick, Mass) and 22-gauge Fork-tip FNB needle (SharkCore, Medtronic)) with randomization of the ord...

Restoration of Chronotropic Competence in Heart Failure Patients With Normal Ejection Fraction

This study will look at how pacing your heart may assist your daily activities and how you are feeling.

Bronchial Thermoplasty 10+ Year Study

To confirm the long-term efficacy and safety of Bronchial Thermoplasty (BT) at 10 years follow-up or beyond in subjects previously enrolled in any of the following Boston Scientific-sponsored, controlled pre-approval studies: AIR, RISA and AIR2.

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.) to prevent device related thrombus.

Biomarkers to Guide Directional DBS for Parkinson's Disease

The purpose of this study is to investigate the clinical efficacy of directional DBS electrode technology and whether electrophysiology biomarkers can predict effective contact segments for chronic therapy.

CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation

The objective of the study is to compare different deep brain stimulation (DBS) settings using the commercially approved Boston Scientific Neuromodulation Vercise system.

Ventricular Rate Regularization for Improved Quality of Life in Patients With CHF and AF

Single center investigator initiated sponsored by Guidant Boston Scientific Corp. to evaluate the benefit of ventricular rate regularization (VRR) in patients with congestive heart failure (CHF) and significant atrial fibrillation (AF) burden.

More From BioPortfolio on "Boston Scientific acquires nVision Medical 275m deal"

Quick Search